Lupin Reports Strong Q2 FY2026 Performance with 24% Revenue Growth and 73% Net Income Surge

Lupin Limited , a global pharmaceutical leader, has announced its financial results for the second quarter of fiscal year 2026, showcasing robust growth across key metrics.

Financial Highlights

Lupin's Q2 FY2026 performance demonstrates significant year-over-year improvements:

Metric	Q2 FY2026	Q2 FY2025	YoY Growth
Sales	₹68,314.00 mn	₹54,970.00 mn	24.3%
EBITDA	₹21,376.00 mn	₹13,083.00 mn	63.4%
EBITDA Margin	31.3%	23.8%	750 bps
Net Income	₹14,779.00 mn	₹8,526.00 mn	73.3%

The company's EBITDA margin expanded by 750 basis points to 31.3%, reflecting improved operational efficiency.

Geographical Performance

Lupin's growth was driven by strong performances across various regions:

North America: Sales reached ₹28,720.00 mn, up 46% YoY
India: Sales stood at ₹20,777.00 mn, a 3% YoY increase
EMEA (Europe, Middle East, and Africa): Reported sales of ₹7,082.00 mn, growing 24% YoY
LATAM (Latin America): Achieved sales of ₹3,443.00 mn, an 81% YoY growth
API (Active Pharmaceutical Ingredients): Generated sales of ₹2,568.00 mn, up 13% YoY

Operational Highlights

Lupin maintained its position as the 3rd largest pharmaceutical player in the U.S. generic market by prescriptions.
The company received 6 ANDA approvals from the U.S. FDA and launched 6 products in the U.S. market during the quarter.
Lupin now has 147 generic products in the U.S. market and is the leader in 49 of its marketed generics.
In India, Lupin's formulation sales grew by 8.8% compared to Q2 FY2025, outpacing the Indian Pharmaceutical Market growth of 7.2%.

Strategic Developments

Strengthened Global Specialty Ophthalmology with the acquisition of VISUfarma.
Entered an out-license partnership with Sandoz for Ranibizumab Biosimilar across multiple regions.
Launched a Strategic partnership program expanding PrecisionSphere - Long-Acting Injectable platform developed by Nanomi.

R&D and Compliance

Investment in R&D for the quarter was ₹5,091.00 mn, representing 7.5% of sales.
The company received approval for 6 ANDAs from the U.S. FDA in the quarter.
Cumulative ANDA filings with the U.S. FDA stand at 433, with 341 approvals received to date.
Lupin has 50 First-to-File (FTF) filings, including 20 exclusive FTF opportunities.

Mr. Nilesh Gupta, Managing Director of Lupin Limited, commented, "We are delighted to present one of our strongest performances ever in this second quarter of FY26. We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the U.S., emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments. We intend to leverage the performance of H1 to deliver a strong FY26."

Lupin's strong Q2 FY2026 results underscore its strategic focus on key markets, operational efficiency, and continued investment in research and development. The company's diverse geographical presence and robust product pipeline position it well for sustained growth in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.08%	+0.50%	+0.94%	-4.56%	-9.72%	+113.27%

Lupin Limited , a global pharmaceutical leader, has announced robust financial results for the second quarter of fiscal year 2026, showcasing significant growth across key metrics.

Financial Highlights

Lupin's consolidated performance for Q2 FY2026 demonstrates substantial year-over-year improvements:

Metric	Q2 FY2026	Q2 FY2025	YoY Growth
Sales	₹7,047.50	₹5,674.00	24.20%
EBITDA	₹2,341.70	₹1,339.80	74.70%
Net Income	₹1,478.00	₹852.00	73.34%
EBITDA Margin	33.20%	23.60%	960 bps

The company's EBITDA margin expanded significantly to 33.20%, up 960 basis points from the previous year, indicating improved operational efficiency.

Segment Performance

Lupin reported strong performance across all markets, including the US, emerging markets, and India.

Operational Highlights

Lupin's revenue from operations grew 24.20% to ₹7,047.50 crore, surpassing the analyst poll estimate of ₹6,559.40 crore.
The company's net profit of ₹1,478.00 crore exceeded analyst estimates of ₹1,217.80 crore.

Management Commentary

Mr. Nilesh Gupta, Managing Director of Lupin Limited, described the results as "one of their strongest performances ever" and expressed confidence in delivering a strong FY26.

Market Response

Despite the strong results, Lupin shares ended down 2.11% at ₹1,956.05 on the BSE.

Lupin's impressive Q2 results reflect the company's strategic initiatives and operational excellence, positioning it for continued growth in the global pharmaceutical market.